Brief: Oncology Institute Sees 2023 Revenue Of $290 To $320 Million
May 10 (Reuters) - Oncology Institute Inc TOI.O :
* ONCOLOGY INSTITUTE INC - SEES 2023 REVENUE OF $290 TO $320
MILLION, REPRESENTING ABOUT 15% TO 27% GROWTH OVER 2022 REVENUE
* ONCOLOGY INSTITUTE INC - SEES 2023 ADJUSTED EBITDA LOSS OF
$25
MILLION TO $28 MILLION
* ONCOLOGY INSTITUTE INC - QTRLY LOSS PER SHARE $0.33
Source text for Eikon: ID:
Further company coverage: TOI.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Starling Oncology
See all newsBrief: Starling Oncology Unit Enters Credit Agreement On August 20
Brief: Starling Oncology Q2 EPS USD -0.08
Brief: Oncology Institute Rebrands As Starling Oncology
Oncology Institute Q1 revenue rises on specialty pharmacy growth, reaffirms 2026 revenue guidance
Brief: Oncology Institute Q1 Gross Profit USD 23.3 Million